In patients with Type 1 monoclonal cryoglobulinemia (MoC), treating the underlying clonal disorder resulted in symptom improvement or stabilization in most, according to a study involving 102 individuals. Additionally, cryoglobulin disappeared in more than half. Participants were diagnosed with Type 1 MoC between 1990 and 2015. Among the results:

• Symptoms were seen in 87% of patients.
• These included cutaneous symptoms (63%), neurological findings (32%), vasomotor symptoms (25%), arthralgias (24%), and renal manifestations (14%).
• Underlying lymphoproliferative disorders were seen in 92%, including monoclonal gammopathy of undetermined significance, myeloma, and lymphoplasmacytic lymphoma.
• Treatment was initiated in 72% of patients, primarily for cryoglobulinemia-related symptoms.
• Treatments included steroids ± alkylating agents, novel myeloma therapies, rituximab with alkylating agents, and rituximab ± steroids.
• 6 patients underwent autologous stem cell transplant.
• Cryocrit at treatment initiation, change in cryocrit, and time to nadir cryocrit predicted improved symptoms.